Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q2 2026 · 10-Q
Revenue$0.00$0.00— vs Q2 2025 Net Income-$44.10K-$44.10KN/M vs Q2 2025 EPS Diluted$0.00$0.00— vs Q2 2025 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
-$72,963
N/M
Operating Cash Flowderived-$30,549N/M ended Feb 28, 2026 · filed Apr 14, 2026 · 45 d after period end